Thrombosis Research
Volume 125, Issue 3 , Pages 220-223 , March 2010

Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients

  • Matthew T. Rondina

      Affiliations

    • Departments of Internal Medicine, University of Utah, Salt Lake City, Utah, 84132, USA
    • Corresponding Author InformationCorresponding author. University of Utah, Department of Internal Medicine 50 North Medical Drive, Room 4B120 SLC, Utah 84132, USA. Tel.: +1 801 581 7818; fax: +1 801 585 1393.
    • ,
  • Michelle Wheeler

      Affiliations

    • Pharmacy University of Utah, Salt Lake City, Utah, 84132, USA
    • ,
  • George M. Rodgers

      Affiliations

    • Departments of Internal Medicine, University of Utah, Salt Lake City, Utah, 84132, USA
    • ,
  • Leslie Draper

      Affiliations

    • Pharmacy University of Utah, Salt Lake City, Utah, 84132, USA
    • ,
  • Robert C. Pendleton

      Affiliations

    • Departments of Internal Medicine, University of Utah, Salt Lake City, Utah, 84132, USA

Received 31 October 2008 ,Revised 27 January 2009 ,Accepted 5 February 2009.

References 

  1. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800
  2. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879
  3. Spyropoulos AC. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest. 2005;128:958–969
  4. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39:215–231
  5. Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. J Clin Endocrinol Metab. 2008;93:S1–8
  6. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001;21:218–234
  7. Kovacs MJ, Weir K, MacKinnon K, Keeney M, Brien WF, Cruickshank MK. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res. 1998;91:137–142
  8. Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost. 1987;57:97–101
  9. Vitoux JF, Aiach M, Roncato M, Fiessinger JN. Should thromboprophylactic dosage of low molecular weight heparin be adapted to patient's weight?. Thromb Haemost. 1988;59:120
  10. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg. 2003;90:547–548
  11. Clagett GP, Anderson FA, Geerts W, Heit JA, Knudson M, Lieberman JR, et al. Prevention of venous thromboembolism. Chest. 1998;114:531S–560S
  12. Rocha AT, de Vasconcellos AG, da Luz Neto ER, Araujo DM, Alves ES, Lopes AA. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obes Surg. 2006;16:1645–1655
  13. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72:308–318
  14. Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116:41–50
  15. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31:42–48
  16. Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Leathers T, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87:817–823
  17. Samama MM, C V , L C . Relation between weight, obesity, and frequency of deep vein thrombosis after enoxaparin in orthopedic surgery [abstr]. Thromb Haemost. 1995;73:977
  18. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg. 2005;15:1368–1374
  19. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg. 2008;18:162–166
  20. Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med. 2007;13:409–413
  21. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26(Suppl 2):24–38
  22. Forestieri P, Quarto G, De Caterina M, Cuocolo A, Pilone V, Formato A, et al. Prophylaxis of thromboembolism in bariatric surgery with parnaparin. Obes Surg. 2007;17:1558–1562
  23. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:141S–159S
  24. Geerts W, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism. Chest. 2008;133:381S–453S

PII: S0049-3848(09)00098-X

doi: 10.1016/j.thromres.2009.02.003

Thrombosis Research
Volume 125, Issue 3 , Pages 220-223 , March 2010

Article Tools

* Image Usage & Resolution